13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802630
Total reported value
$2.9B
$2.9B
88 檔
22.1%
At the close of Q3 2025, Soleus Capital Management, L.P. disclosed equity holdings valued at approximately $2.9B, spread across 88 reported holdings.
In Q3 2025, Soleus Capital Management, L.P. displayed an active expansion posture, initiating 18 new positions and adding to 12 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 9.05% | -0.03% | +10.39% | |
| 2 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 6.99% | +0.12% | +71.34% | |
| 3 | NVCR | NovoCure Limited | Stock-Healthcare | 6.27% | +0.55% | +39.69% | |
| 4 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 5.80% | — | +53.33% | |
| 5 | ELV | Elevance Health Inc | Stock-Healthcare | 4.22% | — | +270.93% | |
| 6 | BBNX | Beta Bionics Inc | Stock-Other | 3.87% | +0.60% | +1.31% | |
| 7 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.17% | -0.29% | -28.50% | |
| 8 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.07% | — | -0.49% | |
| 9 | CELC | Celcuity Inc | Stock-Other | 2.93% | +0.20% | -60.86% | |
| 10 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 2.72% | +1.77% | +568.06% | |
| 11 | TWST | Twist Bioscience CORP | Stock-Other | 2.64% | -1.99% | +426.59% | |
| 12 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.58% | +0.54% | +61.92% | |
| 13 | ORGO | Organogenesis Holdings Inc | Stock-Other | 2.58% | -0.12% | -1.71% | |
| 14 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.43% | -0.75% | -1.33% | |
| 15 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.38% | — | +6.70% | |
| 16 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.29% | -2.26% | -11.13% | |
| 17 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.86% | — | — | |
| 18 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 1.78% | — | — | |
| 19 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.58% | — | +754.20% | |
| 20 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.57% | -0.07% | +570.52% | |
| 21 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.56% | -0.40% | +84.24% | |
| 22 | AXGN | Axogen Inc | Stock-Other | 1.55% | -0.82% | +18.31% | |
| 23 | NPCE | Neuropace Inc | Stock-Other | 1.54% | +0.03% | +27.89% | |
| 24 | GRFS | Grifols Sa-adr | Stock-Other | 1.25% | — | -56.57% | |
| 25 | GERN | Geron CORP | Stock-Other | 1.19% | -0.61% | +7.13% | |
| 26 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.13% | +0.63% | — | |
| 27 | IART | Integra Lifesciences Holding | Stock-Other | 1.04% | — | +3.82% | |
| 28 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.98% | — | — | |
| 29 | ANAB | Anaptysbio Inc | Stock-Other | 0.97% | -0.01% | EXIT | |
| 30 | FOCL | Edap Tms SA -adr | Stock-Other | 0.84% | +0.20% | — | |
| 31 | PHVS | Pharvaris N.V. | Stock-Other | 0.81% | +0.07% | -11.72% | |
| 32 | VCEL | Vericel CORP | Stock-Other | 0.79% | -1.08% | +877.28% | |
| 33 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.79% | +0.13% | +1.07% | |
| 34 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.78% | +0.27% | NEW | |
| 35 | VCYT | Veracyte Inc | Stock-Other | 0.73% | -0.37% | -41.01% | |
| 36 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 37 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.68% | +0.52% | -68.92% | |
| 38 | STAA | Staar Surgical Co | Stock-Other | 0.68% | -0.02% | EXIT | |
| 39 | SION | Sionna Therapeutics Inc | Stock-Other | 0.61% | -0.21% | +9.97% | |
| 40 | CGON | Cg Oncology Inc | Stock-Other | 0.59% | -0.04% | +87.10% | |
| 41 | QURE | uniQure N.V. | Stock-Other | 0.59% | — | — | |
| 42 | QDEL | Quidelortho CORP | Stock-Other | 0.56% | — | +115.52% | |
| 43 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.55% | -1.20% | -50.22% | |
| 44 | ADMA | Adma Biologics Inc | Stock-Healthcare | 0.54% | — | +321.71% | |
| 45 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.52% | +0.02% | — | |
| 46 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.51% | -1.27% | — | |
| 47 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 0.48% | — | — | |
| 48 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 0.47% | +2.48% | -49.86% | |
| 49 | EOLS | Evolus Inc | Stock-Other | 0.45% | -0.17% | -31.57% | |
| 50 | VSTM | Verastem Inc | Stock-Other | 0.42% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | +3.3% | +10.39% | Add |
| 2 | INSP | Inspire Medical Systems Inc | +2.3% | +568.06% | Add |
| 3 | 430 | Terns Pharmaceuticals Inc | +1.5% | -0.49% | Trim |
| 4 | ARGX | Argenx Se - Adr | +1.4% | +61.92% | Add |
| 5 | CELC | Celcuity Inc | +1.1% | -60.86% | Trim |
| 6 | GERN | Geron CORP | +0.9% | +7.13% | Add |
| 7 | BBNX | Beta Bionics Inc | +0.9% | +1.31% | Add |
| 8 | SNDX | Syndax Pharmaceuticals Inc | +0.8% | +84.24% | Add |
| 9 | ANAB | Anaptysbio Inc | +0.8% | +95.00% | Add |
| 10 | ANIP | Ani Pharmaceuticals Inc | +0.5% | +570.52% | Add |
| 11 | SION | Sionna Therapeutics Inc | +0.4% | +9.97% | Add |
| 12 | MDGL | Madrigal Pharmaceuticals Inc | 0% | +754.20% | Add |
| 13 | UTHR | United Therapeutics CORP | -0.3% | -28.50% | Trim |
| 14 | NUVL | Nuvalent Inc-a | -0.7% | -29.60% | Trim |
| 15 | NVCR | NovoCure Limited | -0.8% | +39.69% | Add |
| 16 | RIGL | Rigel Pharmaceuticals Inc | -1% | -49.86% | Trim |
| 17 | TGTX | Tg Therapeutics Inc | -1.1% | +71.34% | Add |
| 18 | INSM | Insmed Inc | -1.5% | -96.50% | Trim |
| 19 | IOVA | Iovance Biotherapeutics Inc | -1.8% | -70.06% | Trim |
| 20 | GRFS | Grifols Sa-adr | -2.4% | -56.57% | Trim |
| 21 | STAA | Staar Surgical Co | -2.6% | -83.25% | Trim |
| 22 | BMRN | Biomarin Pharmaceutical Inc | -3.1% | -1.33% | Trim |
| 23 | ELV | Elevance Health Inc | — | NEW | New buy |
| 24 | TWST | Twist Bioscience CORP | — | NEW | New buy |
| 25 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 26 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
| 27 | INDV | Indivior Pharmaceuticals, Inc. | — | NEW | New buy |
| 28 | SU6 | Surmodics Inc | — | EXIT | Sold out |
| 29 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
| 30 | HO1 | Hologic Inc | — | EXIT | Sold out |
| 31 | ✓ | Merus N V | — | EXIT | Sold out |
| 32 | VCEL | Vericel CORP | — | NEW | New buy |
| 33 | BLTE | Belite Bio Inc - Adr | — | NEW | New buy |
| 34 | VCYT | Veracyte Inc | — | NEW | New buy |
| 35 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 36 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 37 | SNY | Sanofi-adr | — | EXIT | Sold out |
| 38 | QURE | uniQure N.V. | — | NEW | New buy |
| 39 | QDEL | Quidelortho CORP | — | NEW | New buy |
| 40 | MIRM | Mirum Pharmaceuticals Inc | — | NEW | New buy |
| 41 | ADMA | Adma Biologics Inc | — | NEW | New buy |
| 42 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 43 | GMED | Globus Medical Inc - A | — | NEW | New buy |
| 44 | OFIX | Orthofix Medical Inc | — | EXIT | Sold out |
| 45 | TNDM | Tandem Diabetes Care Inc | — | EXIT | Sold out |
| 46 | GSK | Gsk Plc-spon Adr | — | NEW | New buy |
| 47 | SRRK | Scholar Rock Holding CORP | — | EXIT | Sold out |
| 48 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 49 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 50 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Soleus Capital Management, L.P. reported a total U.S. public equity portfolio value of $2.9B across 88 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KRYS, TGTX, NVCR) accounted for 22.1% of total reported equity market value during Q3 2025.
Top New Position Initiated
ELV
市值: $83.9M
Top Position Liquidated / Trimmed
SU6
前期市值: $24.1M
During Q3 2025, Soleus Capital Management, L.P.'s top holdings by market value included KRYS (9.1%)、TGTX (7.0%)、NVCR (6.3%). The largest single position, KRYS, represented 9.1% of total portfolio value.
In Q3 2025, Soleus Capital Management, L.P. made 50 total portfolio adjustments, initiating 18 new buys, adding to 12 positions, trimming 10 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.